Myopic Choroidal Neovascularization

Also known as: Myopic choroidal neovascularization (disorder) / Myopic choroidal neovascularisation / Choroidal neovascularisation / Choroidal neovascularization

Drug	Drug Name	Drug Description
DB08885	Aflibercept	A vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy, and metastatic colorectal cancer
DB01270	Ranibizumab	A recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.

Drug	Drug Name	Target	Type
DB08885	Aflibercept	Vascular endothelial growth factor A	target
DB08885	Aflibercept	Placenta growth factor	target
DB08885	Aflibercept	Vascular endothelial growth factor B	target
DB01270	Ranibizumab	Vascular endothelial growth factor A	target

Drug	Drug Name	Phase	Status	Count
DB01270	Ranibizumab	4	Unknown Status	1
DB08885	Aflibercept	Not Available	Completed	1